SUTAB: payments to doctors
Payments that named SUTAB as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $666K
- Providers
- 11,058
- Transactions
- 28,296
- Average per transaction
- $24
The per-transaction average — $24 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,058 providers the average total is $60, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Braintree Laboratories, Inc. | $663,496 | 99.6% |
| Azurity Pharmaceuticals, Inc. | $2,107 | 0.3% |
| Sebela Pharmaceuticals Inc. | $784 | 0.1% |